With Al­im­ta patent cliff loom­ing, Lil­ly plots stronger foothold in front­line NSCLC with Cyra­mza

With Lil­ly’s foothold in the non-small cell lung can­cer (NSCLC) field weak­en­ing as its Al­im­ta fran­chise march­es to­ward a patent cliff, an­oth­er can­cer treat­ment man­u­fac­tured …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER